SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

SGLT inhibition in kidney disease key lessons from EMPAREG OUTCOME
10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
  • Overview

    Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

  • Educational information

    This lecture was part of a CME accredited symposium: Epigenetics in CKD & CVD: A potential breakthrough therapy? held at ERA-EDTA in Copenhagen, Denmark.

  • Faculty

    Professor Christoph Wanner, MD - University of Würzburg, Germany

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free